News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
